


## Data Sheet

<b>Product Name:</b>	CeMMEC1
<b>Cat. No.:</b>	CS-0040872
<b>CAS No.:</b>	440662-09-9
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	336.34
<b>Target:</b>	DNA/RNA Synthesis; Epigenetic Reader Domain
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics
<b>Solubility:</b>	DMSO : 100 mg/mL (297.32 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

CeMMEC1 is an inhibitor of **BRD4**, and also has high affinity for **TAF1**, with an **IC<sub>50</sub>** of 0.9  $\mu$ M for TAF1, and a **K<sub>d</sub>** of 1.8  $\mu$ M for TAF1 (2). IC<sub>50</sub> & Target: K<sub>d</sub>: 1.8  $\mu$ M (TAF1 (2))<sup>[1]</sup>

IC<sub>50</sub>: 0.9  $\mu$ M (TAF1)<sup>[1]</sup> *In Vitro*: CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC<sub>50</sub> of 0.9  $\mu$ M for TAF1, and a K<sub>d</sub> of 1.8  $\mu$ M for TAF1 (2) and also shows high affinity for the bromodomains of CREBBP, EP300, BRD9. CeMMEC1 (1, 10, 20  $\mu$ M) decreases the number of THP1 cells in S phase in a dose manner. CeMMEC1 also induces apoptosis. CeMMEC1 in combination with (S)-JQ1 displays potentially impaired cell viability than treatment alone<sup>[1]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Kinase Assay:** <sup>[1]</sup>**TAF1** binding assays are conducted using the EPIgeneous Binding Domain kit B. Binding is determined by the displacement of an acetylated biotin peptide from a GST-tagged TAF1 protein using HTRF with a Eu<sup>3+</sup>-conjugated GST antibody donor and streptavidin-conjugated acceptor. Compounds (**CeMMEC1**) are dispensed into assay plates, ProxiPlate-384 Plus using an Echo 525 Liquid Handler. Binding assays are conducted in a final volume of 20  $\mu$ L with 5 nM TAF1-GST, 50 nM peptide (SGRGK (ac)GGK (ac)GLGK (ac)GGAK (ac)RHRK (biotin)-acid), 6.25 nM Streptavidin-XL665, 1:200 Anti-GST-Eu<sup>3+</sup> cryptate and 0.1% DMSO. Assay reagents are dispensed into plates using a Multidrop combi and incubated at room temperature for 3 h. Fluorescence is measured using a PHERAstar microplate reader using the HTRF module with dual emission protocol (A = excitation of 320 nm, emission of 665 nm, and B = excitation of 320 nm, emission of 620 nm). Raw data are processed to give an HTRF ratio (channel A/B  $\times$  10,000), which is used to generate IC<sub>50</sub> curves<sup>[1]</sup>. **Cell Assay:** <sup>[1]</sup>Cells are seeded on clear flat-bottom 96-well or 384-well plates and treated with the indicated compounds (**CeMMEC1**) for the specified conditions. Live-cell imaging pictures are taken with the Operetta High Content Screening System, 20 $\times$  objective and nonconfocal mode<sup>[1]</sup>.

### References:

[1]. Sdelci S, et al. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nat Chem Biol. 2016 Jul;12(7):504-10.

### CAIndexNames:

4-Isoquinolinecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,2-dihydro-2-methyl-1-oxo-

### SMILES:

O=C(C(C1=C2C=CC=C1)=CN(C)C2=O)NC3=CC=C(OCCO4)C4=C3

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA